Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells

Vaccine

Volumn 27, Issue 2, 2009, Pages 250-259

  Betting, David J ^a   Mu, Xi Y ^b   Kafi, Kamran ^a   McDonnel, Desmond ^b   Rosas, Francisco ^b   Gold, Daniel P ^b   Timmerman, John M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Favrille Inc   (United States)

Author keywords

Baculovirus; Tumor antigen; Vaccination

Indexed keywords

ANTIGEN; CARRIER PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; IMMUNOGLOBULIN IDIOTYPE KEYHOLE LIMPET HEMOCYANIN CONJUGATE; KEYHOLE LIMPET HEMOCYANIN; MALEIMIDE; MANNOSE RECEPTOR; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BACULOVIRUS; CD8+ T LYMPHOCYTE; CONJUGATION; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; GLYCOSYLATION; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INSECT CELL; LYMPHOMA; MOUSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TREATMENT RESPONSE; VACCINATION; VIRUS RECOMBINANT;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; BACULOVIRIDAE; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; HYBRIDOMAS; IMMUNIZATION; IMMUNOGLOBULIN IDIOTYPES; LECTINS, C-TYPE; LYMPHOMA; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED BALB C; RECEPTORS, CELL SURFACE; SPODOPTERA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 57149086271     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.055     Document Type: Article

References (48)

1. Timmerman J.M. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma. Adv Pharmacol (San Diego, Calif) 51 (2004) 271-293
2. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 May(6835) (2001) 380-384
3. Timmerman J.M., and Levy R.L. The history of the development of vaccines for lymphoma. Clin Lymph 1 (2000) 129-139
4. Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A., and Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327 17 (1992) 1209-1215
5. Hsu F.J., Caspar C.B., Czerwinski D., Kwak L.W., Liles T.M., Syrengelas A., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89 9 (1997) 3129-3135
6. Bendandi M., Gocke C.D., Kobrin C.B., Benko F.A., Sternas L.A., Pennington R., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [see comments]. Nat Med 5 10 (1999) 1171-1177
7. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 5 (2002) 1517-1526
8. Redfern C.H., Guthrie T.H., Bessudo A., Densmore J.J., Holman P.R., Janakiraman N., et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 24 July(19) (2006) 3107-3112
9. Koc O., Redfern C., Wiernik P.H., Rosenfelt F., Winter J., Guthrie T.H., et al. Id/KLH vaccine (FavId TM) following treatment with rituximab: an analysis of response rate immprovement (RRI) and time-to-progression (TTP) in follicular lymphoma (FL). Blood 104 (2004) 170a [abstract #587]
10. Hurvitz S.A., and Timmerman J.M. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol 17 September(5) (2005) 432-440
11. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 September(7161) (2007) 419-426
12. Apostolopoulos V., and McKenzie I.F. Role of the mannose receptor in the immune response. Curr Mol Med 1 September(4) (2001) 469-474
13. Cambi A., and Figdor C.G. Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol 15 October(5) (2003) 539-546
14. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., and Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316 April(5824) (2007) 612-616
15. Burgdorf S., Lukacs-Kornek V., and Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 176 June(11) (2006) 6770-6776
16. He L.Z., Crocker A., Lee J., Mendoza-Ramirez J., Wang X.T., Vitale L.A., et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 178 May(10) (2007) 6259-6267
17. Engering A.J., Cella M., Fluitsma D., Brockhaus M., Hoefsmit E.C., Lanzavecchia A., et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 27 September(9) (1997) 2417-2425
18. Sallusto F., Cella M., Danieli C., and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182 August(2) (1995) 389-400
19. Srinivas O., Larrieu P., Duverger E., Boccaccio C., Bousser M.T., Monsigny M., et al. Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting. Bioconjugate Chem 18 September-October(5) (2007) 1547-1554
20. Tan M.C., Mommaas A.M., Drijfhout J.W., Jordens R., Onderwater J.J., Verwoerd D., et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 27 September(9) (1997) 2426-2435
21. Altmann F., Staudacher E., Wilson I.B., and Marz L. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconjugate J 16 February(2) (1999) 109-123
22. Kost T.A., and Condreay J.P. Recombinant baculoviruses as expression vectors for insect and mammalian cells. Curr Opin Biotechnol 10 October(5) (1999) 428-433
23. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 November(9447) (2004) 1757-1765
24. Cox M.M. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Therap 10 February(1) (2008) 56-61
25. Yao Q., Bu Z., Vzorov A., Yang C., and Compans R.W. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 21 January(7-8) (2003) 638-643
26. Shrestha M.P., Scott R.M., Joshi D.M., Mammen Jr. M.P., Thapa G.B., Thapa N., et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 356 March(9) (2007) 895-903
27. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24 April(17) (2006) 3624-3631
28. van Oers M.M. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv Virus Res 68 (2006) 193-253
29. Neidhart J., Allen K.O., Barlow D.L., Carpenter M., Shaw D.R., Triozzi P.L., et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 22 January(5-6) (2004) 773-780
30. Lodge P.A., Childs R.A., Monahan S.J., McLean J.G., Sehgal A., Boynton A.L., et al. Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells. J Immunother 22 July(4) (1999) 346-355
31. Soares M., Hanisch F.G., Finn O.J., and Ciborowski P. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity. Protein Expr Purif 22 June(1) (2001) 92-100
32. Tso C.L., Zisman A., Pantuck A., Calilliw R., Hernandez J.M., Paik S., et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 61 November(21) (2001) 7925-7933
33. Ullenhag G.J., Frodin J.E., Jeddi-Tehrani M., Strigard K., Eriksson E., Samanci A., et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 10 May(10) (2004) 3273-3281
34. Hurvitz S.A., and Timmerman J.M. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther 5 June(6) (2005) 841-852
35. Betting D.J., Kafi K., Abdollahi-Fard A., Hurvitz S.A., and Timmerman J.M. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior anti-tumor immunity against B cell lymphomas. J Immunol 181 September(15) (2008) 4131-4140
36. Campbell M.J., Carroll W., Kon S., Thielemans K., Rothbard J.B., Levy S., et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 139 8 (1987) 2825-2833
37. Deslee G., Charbonnier A.S., Hammad H., Angyalosi G., Tillie-Leblond I., Mantovani A., et al. Involvement of the mannose receptor in the uptake of Der p 1, a major mite allergen, by human dendritic cells. J Allergy Clin Immunol 110 November(5) (2002) 763-770
38. Ma S., and Nashabeh W. Carbohydrate analysis of a chimeric recombinant monoclonal antibody by capillary electrophoresis with laser-induced fluorescence detection. Anal Chem 71 November(22) (1999) 5185-5192
39. Presicce P., Taddeo A., Conti A., Villa M.L., and Della Bella S. Keyhole limpet hemocyanin induces the activation and maturation of human dendritic cells through the involvement of mannose receptor. Mol Immunol 45 February(4) (2008) 1136-1145
40. Pietrella D., Corbucci C., Perito S., Bistoni G., and Vecchiarelli A. Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation. Infect Immun 73 February(2) (2005) 820-827
41. Miller R.A., Maloney D.G., Warnke R., and Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306 9 (1982) 517-522
42. Timmerman J.M., and Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 164 9 (2000) 4797-4803
43. Weng W.K., Czerwinski D., Timmerman J., Hsu F.J., and Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 22 December(23) (2004) 4717-4724
44. Zhu D., McCarthy H., Ottensmeier C.H., Johnson P., Hamblin T.J., and Stevenson F.K. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99 April(7) (2002) 2562-2568
45. Markl J., Lieb B., Gebauer W., Altenhein B., Meissner U., and Harris J.R. Marine tumor vaccine carriers: structure of the molluscan hemocyanins KLH and htH. J Cancer Res Clin Oncol 127 October(Suppl 2) (2001) R3-R9
46. Favrille Press Release, May 27, 2008: Favrille announces results from phase 3 registration trial of specified in patients with follicular B-cell non-Hodgkin's lymphoma: results fail to show statistically significant improvement in primary endpoint, time to progression, compared to control [www.favrille.com].
47. Levy R, Robertson MJ, Ganjoo K, Leonard JP, Vose J, Denney D. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). In: Proceedings of the 99th annual meeting of the American Association for Cancer Research. San Diego, CA Philadelphia (PA): AACR; 2008 [abstract LB-204 2008].
48. Biovest Press Release, July 21, 2008: Biovest reports results for patients treated with anti-cancer vaccine: BiovaxID(R) demonstrates clinically and statistically significant improvement of disease-free survival in non-Hodgkin's lymphoma in pivotal phase 3 clinical trial [www.vcall.com/IC/GenReleaseasp?ID=132297].